Replies to post #143422 on Biotech Values

[DewDiligence]

I will add this FoB partnership to the compilation in the iBox.

[DewDiligence]

Is Merck KGaA FoB partnership with RDY inked in 2012 (#msg-76359649) defunct? This piece from FiercePharma mentions it not at all:

http://www.fiercepharma.com/story/merck-kgaa-pour-138m-biosimilars-licensing-instead-ma/2014-05-09

Merck KGaA has plenty of resources to devote to big M&A deals… But company executives told shareholders at its annual meeting on Friday that future growth may be less about giant acquisitions than it is about making strategic deals and internal changes to boost its pipeline.

Toward that end, the company is searching for pharma licensing deals and planning to invest €100 million ($138 million) in biosimilars, according to a company statement.

[DewDiligence]

Merck KGaA wants to ditch FoB partnership with RDY:

http://www.fiercepharma.com/pharma/merck-kgaa-advanced-talks-to-sell-off-biosims-unit-and-others-could-follow

The collaboration announced five years ago (#msg-76359649) has yet to produce any regulatory approvals.